ArticleBMJ open2020

Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.

Monique K van der Kooij et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.